Chemotherapeutic properties of epigallicatechin-3-gallate in lung carcinogenesis
M Cromie - 2016 - ttu-ir.tdl.org
Our previous study examined the role of natural products in the acute treatment of normal
human lung epithelial cells, BEAS-2B, to biologically relevant concentrations of BaP. Since …
human lung epithelial cells, BEAS-2B, to biologically relevant concentrations of BaP. Since …
The Importance of the Insulin-like Growth Factor Signaling Pathway in Lung Cancer and the Potential of its Components as Therapeutic Targets
SE Franks - 2015 - atrium.lib.uoguelph.ca
Lung cancer is the leading cause of cancer-related mortalities worldwide. Despite the
introduction of new therapeutics, there has been very little improvement in survival for …
introduction of new therapeutics, there has been very little improvement in survival for …
Second German-Catalan workshop on epigenetics & cancer
B Gonzalez, SV Forcales, M Perucho - Epigenetics, 2015 - Taylor & Francis
The Second German-Catalan Workshop on Epigenetics and Cancer was held in Barcelona
on November 19–21, 2014. The workshop brought together, for the second time, scientists …
on November 19–21, 2014. The workshop brought together, for the second time, scientists …
Novel and Emerging Agents in NSCLC
AS Tsao, JA Roth - Lung Cancer, 2014 - Wiley Online Library
This chapter will review the latest emerging novel targeted agents and gene therapy in
nonsmall cell lung cancer treatment. In the targeted therapies section, each class of drug will …
nonsmall cell lung cancer treatment. In the targeted therapies section, each class of drug will …
[PDF][PDF] Docteur en Sciences
ADELAP INTEGRATIVE - theses.hal.science
Le concept de la pathologie dite «intégrative» dans le domaine de l'oncologie est centré sur
la recherche pré clinique et/ou sur la recherche translationnelle, assurant le lien entre la …
la recherche pré clinique et/ou sur la recherche translationnelle, assurant le lien entre la …
Development and optimization of a methodology to synthetize chitosan/cetuximab conjugates for encapsulate siRNA and targeting to EGFR overexpressing cells
JAP Mota - 2014 - repositorio.cespu.pt
O uso terapêutico de Small Interfering RNA (siRNA) tem sido observado como uma
potencial nova abordagem para o tratamento do cancro. O desafio-chave no campo clínico …
potencial nova abordagem para o tratamento do cancro. O desafio-chave no campo clínico …
H προγνωστική σημασία των κυκλοφορούντων διαλυτών μορίων προσκόλλησης σε ασθενείς με μικροκυτταρικό καρκίνο πνεύμονα: συσχέτιση με κλινικές και …
Η Κοττέας - 2014 - didaktorika.gr
Σκοπός: Η επιθηλιακή Ε-καντερίνη, το διακυτταρικό μόριο προσκόλλησης-1 (ΙCAM-1),
τοαγγειακό μόριο προσκόλλησης-1 (VCAM-1) και η ενδοθηλιακή Ε-σελεκτίνη …
τοαγγειακό μόριο προσκόλλησης-1 (VCAM-1) και η ενδοθηλιακή Ε-σελεκτίνη …
[PDF][PDF] Docteur en Sciences
I Marius - 2013 - Citeseer
Le concept de la pathologie dite «intégrative» dans le domaine de l'oncologie est centré sur
la recherche pré clinique et/ou sur la recherche translationnelle, assurant le lien entre la …
la recherche pré clinique et/ou sur la recherche translationnelle, assurant le lien entre la …
Contribution of the integrative pathology to the discovery of biomarkers for non-small cell lung cancer: integrative pathology and lung cancer
MI Ilie - 2013 - theses.hal.science
The non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths in the world.
Reliable and validated biomarkers could represent a possible breakthrough in the …
Reliable and validated biomarkers could represent a possible breakthrough in the …
[PDF][PDF] Erlotinib no tratamento do cancro do pulmão não pequenas células em progressão
T Gomes, A Fernandes, CH de Trás-os-Montes… - Revista do Grupo de …, 2013 - gecp.pt
Introdução: O erlotinib, um inibidor do domínio tirosinacinase do recetor do fator de
crescimento epidérmico, está aprovado no tratamento do carcinoma pulmonar de não …
crescimento epidérmico, está aprovado no tratamento do carcinoma pulmonar de não …